Identify risk factors for significant morbidity and mortality that are associated with HF, particularly post hospitalization

This case-based enduring activity will cover the diagnosis, treatment and management of patients with dyslipidemia.

Key points for incorporating PCSK9 inhibitors into clinical practice and tips to facilitate patient access will be included to broaden clinicians’ armamentarium of lipid-lowering treatments

Practical overview of current trends in treatment for chronic HF. Improve therapeutic decision making for patients with chronic HF. Reducing rehospitalizations and improving patient outcomes.

Etiology and pathophysiology of cardiometabolic syndrome and the development of cardiovascular disease in people with type 2 diabetes

Assess the type, stage and functional classification of heart failure in hospitalized patients and develop a plan for patients hospitalized with heart failure with reduced ejection fraction (HFrEF)

Identify those patient populations most likely to present with or develop hyperkalemia, and utilize the appropriate conventional and/or novel agents to correct subacute hyperkalemia.

A series of patient cases with increasing severity of kidney disease will exemplify the treatments and strategies for improving patient outcomes.

Key clinical findings from recent trials related to antithrombotic management of patients with AF who have an ACS or have undergone PCI